

INNOMEDCATALYST

STARTUP DEMO DAY

Innovative Startups in 5P Digital Medicine

Bologne, November 14, 2025

Investors E-Book

Funded by the European Union

INNOMEDCATALYST

DEMO DAY InnoMedCatalyst 2025

Holoma

Company Description

HoloMA is a spin off from Interconsult Bulgaria (ICB) since Q3 2022. Its current legal entity is established under the Bulgarian trade law as NX-Xtreme Ltd.

Company Vision & Mission:
Become the leading holographic platform for surgeons across Europe, enabling each surgeon to be more informed and perform safety.

- Increase the knowledge of medical professionals
- Provide the industry with tailored software solutions
- Reduce the complexity for customers
- Address the technical and clinical challenges associated with surgery
- Improve the clinical performance in skeleton reconstructive procedures.

Organization name: NX-Xtreme Ltd

Country: Bulgaria

Type of company: Startup / Spinoff

Year of Foundation: 2021

TRL Level: TRL 6

Expected Revenue for the first 5Y after Market Launch: >1.000.000 €

Funding Instrument: Equity

Investment Required: 2.500.000 €

Product / Solution

HoloMA is Mixed Reality platform that seamlessly integrates physical objects with their virtual counterparts. It superimposes the virtual layers onto the physical objects and creates mixed/extended/ reality environment.
GenAI creates X-Ray images based on the extended reality environment.
HoloMA's Unique Value:

- In emergencies or force majeure it can save lives as doctors can perform assisted operations
- 10x higher precision compared to certified global medical device suppliers
- The only company worldwide supplying hardware agnostic solution
- Near-real time mixed reality navigation
- Digital twins follow the motion of the physical objects in near-real time
- Saving cost for expensive X-Ray Scanners and patient/surgeon health friendly
- Surgeon are much better trained thanks to X-Ray simulation

The product is in MVP stage. Tested in Sheffield /UK/ and UMC Utrecht /NL/.

HoloMA Applications:

1. Medical Universities/ University Hospitals - GenAI assisted Medical Trainings (B2B)
2. Hospitals/ Emergency Medical Services - Intraoperative dynamic real-time navigation (B2B)

CONTACT DETAILS

Bilyana Nikolaeva
E-mail: bnn@icb-m.com
Phone: +359 893 647 141
Website: https://holoma.info/

INNOMEDCATALYST

DEMO DAY InnoMedCatalyst 2025

RareBioTech

Company Description

RareBioTech, S.L. is a precision biotechnology spin-off from the University of Salamanca. It was recently selected by the Salamanca City Council as one of the first biotech companies to join Abioinnova, the city's new biomedical innovation hub. RareBioTech specializes in advanced tools for rare disease research and personalized medicine. Backed by the renowned Biomedicine of Rare Diseases Research Group (GIRBER-USAL), it addresses critical gaps in translational medicine through customized lentiviral vectors, genetically engineered cell lines, and patient-derived organoids. The company's innovation lies in its dual academic-commercial validation, offering R&D solutions while aligning with the 5P Medicine framework. It's scalable business model targets academic labs (60% revenue), pharma (30%), and hospitals (10%), with plans to expand from Spain (2025) to the EU (2026–27) via Horizon Europe partnerships. RareBioTech's validated prototypes, including lentiviral production and organoid platforms, are supported by USAL's infrastructure and a team led by Prof. Dr. Jesus Lacal, a translational genetics expert. The company is an ideal fit for the InnoMedCatalyst project contributing to regional innovation in digital 5P medicine through peer learning, accelerator programs, and interregional investment projects. With €20K seed funding and pending grants, RareBioTech projects gaining revenue by 2027, merging social impact in rare diseases.

Organization name: RareBio Tech, S.L.

Country: Spain

Type of company: Spinoff

Year of Foundation: 2025

TRL Level: TRL 4

Expected Revenue for the first 5Y after Market Launch: 250.000€ - 500.000€

Funding Instrument: Equity

Investment Required: 500.000€

Product / Solution

RareBioTech is a biotechnology company at the forefront of advancing 5P Medicine (Predictive, Preventive, Personalized, Participatory, and Precision Medicine) through innovative B2B solutions. The company specializes in developing state-of-the-art research tools to accelerate discoveries in rare diseases and facilitate translational medicine. RareBioTech provides high-efficiency lentiviral vectors optimized for gene editing applications, custom genetically modified cell lines for mechanistic studies and target validation, and physiologically relevant epidermal organoids for dermatological research. These offerings support predictive modeling and personalized medicine approaches in both academic and industrial settings.

The company is actively expanding its capabilities to include advanced organoid models (e.g., brain, cardiac) while implementing GMP (Good Manufacturing Practice) standards to ensure product quality and scalability for preclinical applications. By combining cutting-edge biotechnology with the principles of 5P Medicine, RareBioTech serves as a strategic partner for researchers and biopharmaceutical companies, bridging the gap between basic research and therapeutic development. With a strong commitment to innovation and quality, RareBioTech is positioned to play a key role in advancing precision medicine and accelerating the development of novel treatments for rare diseases.

CONTACT DETAILS

Jesús Lacal

E-mail: jlacal@usal.es

Phone: +34 664 320 510

Website: NA

INNOMEDCATALYST

DEMO DAY InnoMedCatalyst 2025

GRIPWISE™

Company Description

Frailty of the elderly is one of the major conditions for the wellness and autonomy of elderlies, costing more than 350 B€ to the European Health Care Systems.

Gripwise is a cloud-based system, with accessories connected to a smart loadcell, gathering data for frailty, fall risk and sarcopenia assessments in a simple and effective workflow. We help professionals to monitor and maintain the health and quality of life of the elderly, through personalized nutrition and physical activity, reducing costs in an ageing society.

In addition, based on its innovative patents, granted in the US and EU, Gripwise allows professionals to assess and train the strength profile of different muscle groups, making possible rehabilitation at distance.

Organization name: Gripwise Tech, Lda

Country: Portugal

Type of company: Startup

Year of Foundation: 2020

TRL Level: TRL 6

Expected Revenue for the first 5Y after Market Launch: 100.000€ - 250.000€

Funding Instrument: Equity

Investment Required: NA

Product / Solution

Gripwise was founded in April 2020 and has ISO 13485 certification (medical devices producer).

Gripwise has developed a GDPR compliant system to empower health professionals to better assess different health conditions, as frailty, fall risk and sarcopenia, and better prescribe nutrition and physical activity to their patients. The solution comprises a digital dynamometer (class 1 medical device), iOS/Android mobile applications and a cloud platform with a webapp for professionals' access from anywhere with internet and a web browser.

It's a solution to be used by professionals (B2B).

CONTACT DETAILS

Ricardo Moura

E-mail: ricardo.moura@gripwisetech.com

Phone: +35 196 259 1198

Website: https://gripwisetech.com

INNOMEDCATALYST

DEMO DAY InnoMedCatalyst 2025

digital rehab

Company Description

DigitalRehab aims to redefine the standards of rehabilitation by making it more effective, sustainable, and accessible. Their mission is to address key challenges such as limited access to therapy, low treatment adherence, and the lack of objective data on home-based exercises. To overcome these barriers and integrate medical devices into clinical practice, it is essential to develop specific therapeutic protocols—still largely absent today—supported by solid clinical evidence. This requires advanced tools capable of accurately monitoring patient progress and improving treatment quality.

This is the foundation of AuReha, a fully integrated hardware and software solution designed to support both patients and therapists throughout the rehabilitation process. The portable, user-friendly device enables patients to perform exercises independently and engagingly at home, while therapists can personalize and optimize recovery pathways using reliable clinical data. AuReha is undergoing CE certification under MDR 2017/745 and is based on an evidence-based approach. It fosters a connected care model, continuously linking patients and professionals to enhance therapeutic outcomes, quality of life, and overall healthcare efficiency.

Organization name: DigitalRehab

Country: Italy

Type of company: Startup

Year of Foundation: 2021

TRL Level: TRL 5

Expected Revenue for the first 5Y after Market Launch: 250.000€ - 500.000€

Funding Instrument: Equity

Investment Required: 350.000€

Product / Solution

AuReha is an integrated system designed to support and monitor upper limb rehabilitation. It consists of a sensorized wearable shirt and a gamified mobile app. The sensors capture real-time patient movements during rehab exercises performed in virtual environments, where patients interact through an avatar guided by a virtual coach. The app calculates an objective clinical score and dynamically adapts the exercises to personalize each training session.

Healthcare professionals manage the rehabilitation plan through a dedicated platform, with access to structured clinical data and performance indicators. This enables continuous therapy monitoring and supports clinical decision-making.

The business model is B2B2C: Direct sales to rehabilitation centers (hospitals, outpatient clinics, affiliated facilities); Rental packages for home use, allowing patients to continue therapy remotely while being monitored by healthcare professionals.

AuReha combines innovation, usability, and clinical value to improve therapy outcomes and accessibility.

CONTACT DETAILS
Silvia Sciamanna
E-mail: sciamanna@digitalrehab.eu
Phone: +39 333 825 6130
Website: https://www.digitalrehab.eu/

Company Description

Integrated Data Solutions or IDS was founded in 2013 to provide the emerging Romanian private healthcare sector with a custom solution, that improves the clinical setting by offering efficacy in patient flow and data management. Since then, the company also has been developing solutions for businesses from multiple European countries, including Belgium and Germany, and from US, working in different domains, ranging from the advertising market to industrial production.

The most promising product is idsClinic, dedicated for all medical personnel to ease their workload and focus on the patient. Its development has been a continuous endeavor of our company from the beginning, and we are always looking for new ways to improve it. With a small, but focused and dedicated team, the company is working effortlessly to grow and bring its product to serve the community. The team's expertise, spanning from computer engineering to healthcare, has proven invaluable to translate medical processes into actual software. The product is already being tested successfully in a couple of clinics, with positive feedback from the customers. We need to expand to other clinics and hospitals. The software is thought to be an off-the-shelf product, requiring little customization, but being able to be updated with new functionality and address new markets.

Organization name: Integrated Data Solutions

Country: Romania

Type of company: Innovative SME

Year of Foundation: 2013

TRL Level: TRL 6

Expected Revenue for the first 5Y after Market Launch: 250.000€ - 500.000€

Funding Instrument: Grant

Investment Required: NA

Product / Solution

Our application, idsClinic, is a B2B healthcare solution and was designed to be a comprehensive solution for medical clinics. It can be used by small clinics to large hospitals, as it contains multiple modular systems, and can be scaled to any number of staff.

While the Electronic Medical Records system is at the core of the application, it is linked to multiple medical modules (Oncology, Radiology, Genetics, Psychology, Nutrition, Pneumology, Urology, Auxiliary), but also includes treatment plans, notifications for unpaid bills, appointment scheduling and many more.

Other modules like the reports and dashboards give insight in both the medical data and the business side of the clinic. With an intuitive and modern UI, our goals is to give back the time to the medical professionals and let them focus on the medical act.

CONTACT DETAILS
Ruxandra Pop-Kun
E-mail: ruxandrapopkun@integratedata.ro
Phone: +40 743 022 773
Website: https://www.integratedata.eu/

INNOMEDCATALYST

DEMO DAY InnoMedCatalyst 2025

thermo-i

Company Description

Thermo-i is a groundbreaking medical robot designed to transform how core body temperature is monitored in healthcare and home environments. Traditional methods, such as rectal probes, are invasive, uncomfortable for patients, and labor-intensive for medical staff. Thermo-i offers a fully autonomous, contactless solution that delivers the same clinical accuracy as the gold-standard rectal probes but operates from a distance of 20–60 cm, ensuring patient comfort, privacy, and hygiene.

The Thermo-i robot is equipped with advanced sensors and AI-driven algorithms, enabling continuous monitoring and generating real-time, validated data for both hospitals and clinical trials. This data can not be manipulated and is tamper-proof, making it ideal for regulatory-compliant clinical research and improving patient safety in critical care environments such as ICUs, pediatrics, and infectious disease departments.
Thermo-i also reduces hospital staff workload by up to 1 hour per shift, eliminates consumable costs, and enhances telemedicine applications by integrating with smart devices and hospital systems. Tested successfully in university hospital ICUs, Thermo-i has amazed doctors with its precision and potential to revolutionize temperature monitoring.

By addressing the critical gaps in temperature monitoring, Thermo-i is positioned to become the new standard in healthcare innovation.

Organization name: Innovariver Ltd./ thermo-i

Country: Bulgaria

Type of company: Startup

Year of Foundation: 2016

TRL Level: TRL 6

Expected Revenue for the first 5Y after Market Launch: >1.000.000€

Funding Instrument: Equity

Investment Required: 5.000.000€

Product / Solution

Thermo-i is an autonomous, contactless medical robot designed to revolutionize core body temperature monitoring in both clinical and non-clinical settings. Unlike traditional methods, such as invasive rectal probes or inconsistent wearable devices, Thermo-i provides precise, real-time core temperature measurements from a distance of 20–60 cm, ensuring unparalleled patient comfort, hygiene, and privacy.

The solution is primarily B2B, targeting hospitals, clinical trial companies, and medical device producers. In hospitals, Thermo-i automates temperature monitoring, reducing nurse workload by up to 1 hour per shift while eliminating consumable costs. Its application is particularly impactful in ICUs, pediatrics, infectious disease, and immunology departments, where continuous and accurate temperature monitoring is critical.

In clinical trials, Thermo-i addresses a significant unmet need for reliable, tamper-proof temperature data that meets regulatory requirements. By automating data collection, it eliminates manual errors, ensuring credibility for official trial reports and enabling faster regulatory approval processes.

Additionally, Thermo-i has future potential as a B2C solution for home use, particularly for patients with chronic illnesses, parents monitoring children's health, and individuals tracking ovulation. Its seamless integration with smart devices and telemedicine platforms ensures its usability in a variety of settings.

CONTACT DETAILS
Mustafa Ahmedov
E-mail: mustafa@thermo-i.com
Phone: +35 989 949 6080
Website: https://thermo-i.com

INNOMEDCATALYST

DEMO DAY InnoMedCatalyst 2025

Onco PharmAI

Smarter oncology decisions.

Company Description

IOncoPharmAI is a MedTech startup based in Iași, Romania (Nord-Est region), developing predictive AI models for oncology clinical decision support. Their mission is to enable personalized chemotherapy by using machine learning to forecast toxicity risk, improve patient safety, and guide dose treatment adaptation. Founded by a multidisciplinary team of oncology specialist, clinical pharmacologist, and AI researcher, OncoPharmAI builds validated, interpretable, and clinically usable tools that fit into hospital workflows and meet regulatory standards.

The flagship product, ToxiReport, is an AI-based solution currently at TRL 4–5, designed to predict chemotherapy-related toxicities and assist healthcare professionals and pharmaceutical companies in early detection and response. The technology integrates a proprietary algorithm trained on real-world oncology data and a large language model (LLM) for pharmacovigilance reporting. Our intellectual property is based on a custom-built, clinically validated model architecture and novel toxicity report aggregation methods.

OncoPharmAI is a B2B solution targeting pharmaceutical companies, regulatory bodies, and hospitals. By embedding predictive analytics into pharmacovigilance workflows, we enable faster decision-making, better patient outcomes, and safer, more personalized cancer treatments.

Organization name: OncoPharmAI

Country: Romania

Type of company: Startup

Year of Foundation: 2023

TRL Level: TRL 5

Expected Revenue for the first 5Y after Market Launch: 250.000€ - 500.000€

Funding Instrument: Grant

Investment Required: NA

Product / Solution

ToxiReport is an AI-based software model designed to support personalized oncology care by predicting treatment-related toxicities and generating digital patient "avatars" to inform clinical decisions. It addresses a critical unmet need in oncology: reducing adverse events and optimizing therapeutic strategies based on individual patient profiles.

Our solution targets both B2B (pharmaceutical companies, clinical trials) and B2C (oncology specialists). By integrating multi-source clinical data with machine learning, ToxiReport delivers predictive insights that improve patient outcomes and streamline treatment decisions.

It includes two core components:

a)A Large Language that reads and synthesizes clinician reports into aggregated toxicity summaries.

b) A Random Forest-based model that forecasts potential chemotherapy-related toxicities using historical data, helping pharmaceutical companies prioritize adverse reactions and enhance drug safety.

We developed a fully proprietary algorithm, retrospectively validated on a cohort of 74 patients with promising results. Currently at TRL 4–5, the next steps include prospective validation and development of a clinically usable interface. Entirely custom-built in-house, our model represents a novel integration of AI in oncology workflows, supporting both patient care and drug development through predictive, data-driven insights.

CONTACT DETAILS

Camelia Dascălu

E-mail: dascalucamelia68@gmail.com

Phone: + 40 729 041 375

Website: NA

INNOMEDCATALYST

DEMO DAY InnoMedCatalyst 2025

plux Biosignals

Company Description

PLUX Biosignals is a Portuguese SME pioneering next-generation wearable biosignal solutions for personalised and precision healthcare. Founded in 2007, we design and manufacture advanced, modular platforms for high-quality physiological signal acquisition—including EMG, ECG, EEG, EDA, respiration, and movement—serving applications in MedTech, clinical research, and digital therapeutics.

Our mission is to unlock the full potential of biosignals to improve lives through early diagnostics, adaptive rehabilitation, and patient-centred care. With global clients in over 60 countries and partnerships with leading universities, hospitals, and innovators, our solutions power breakthroughs in neurotechnology, mental health, and AI-driven healthcare.

PLUX Biosignals is ISO 13485 certified and offers in-house R&D and production, enabling full control from prototyping to integration and validation. Our portfolio includes biosignalsplux (for research), BITalino (mobile prototyping), and OEM technologies embedded in third-party medical devices.

We are proud contributors to European R&D initiatives and champions of open innovation. With a multidisciplinary team and 18 years of field expertise, PLUX Biosignals is uniquely positioned to accelerate personalised, preventive, and participatory healthcare across Europe and beyond.

Organization name: PLUX Biosignals

Country: Portugal

Type of company: Innovative SME

Year of Foundation: 2007

TRL Level: TRL 6

Expected Revenue for the first 5Y after Market Launch: >1.000.000€

Funding Instrument: Grant

Investment Required: 2.500.000€

Product / Solution

PLUX Biosignals is developing the SmartBelt, a wearable medical device designed for continuous, non-invasive monitoring of gastrointestinal (GI) motility. The SmartBelt integrates electrogastrography (EGG) and acoustic sensors into a comfortable abdominal band, capturing real-time physiological data to support early diagnosis, monitoring, and personalised management of GI disorders such as Inflammatory Bowel Disease (IBD) and Irritable Bowel Syndrome (IBS).

Leveraging AI-powered algorithms, the SmartBelt classifies pathological motility patterns, such as fibrosis or dysmotility, automating diagnostic support and reducing dependence on costly, clinic-based equipment or specialist evaluations. This unique combination of continuous, remote monitoring and machine learning enables a shift from episodic clinic visits to proactive, patient-centred care.

The SmartBelt is developed under ISO 13485 standards, currently at TRL 6, and targets the B2B MedTech market, with initial deployment in hospital networks, GI clinics, and research institutions. The business model includes device sales and screening-as-a-service, enabling sustainable revenue generation and scalability. Supported by successful pilot validations and EU-funded projects (e.g., iPrognosis, PROTEIN), the SmartBelt positions PLUX as a leading innovator in digital health and precision gastroenterology across Europe.

CONTACT DETAILS
Rita Cristóvão
E-mail: rcristovao@pluxbiosignals.com
Phone: +35 193 642 6059
Website: https://pluxbiosignals.com

INNOMEDCATALYST

DEMO DAY InnoMedCatalyst 2025

METABLUE

Company Description

Metablue is a medtech startup focused on digital ear care for children. Our innovation, Otitest, is a portable diagnostic device that helps parents detect early signs of otitis media and externa at home. The system integrates medical-grade thermo and rgb sensors with AI-based classification and a gamified educational app, allowing for fast, non-invasive detection and improved decision-making by families and paediatricians.

Metablue is driven by a mission to reduce unnecessary antibiotic use, support early intervention, and empower caregivers. The company has raised €400k in private investment and is currently conducting clinical trials with ENT specialists.

Our solution addresses a clear unmet need in paediatric care and aligns with EU health priorities on antimicrobial resistance and preventive digital tools.

Metablue operates from Porto and has a multidisciplinary team combining healthtech, software, and user experience design expertise. We are now scaling development, pursuing CE certification, and preparing market entry through direct-to-consumer and clinical channels in the EU and US.

Organization name: Metablue Solution Lda

Country: Portugal

Type of company: Startup

Year of Foundation: 2011

TRL Level: TRL 5

Expected Revenue for the first 5Y after Market Launch: >1.000.000€

Funding Instrument: Equity

Investment Required: 200.000€

Product / Solution

Otitest is a smart, portable medical device that allows parents to detect early signs of otitis (middle and outer ear infections) at home. The device uses medical-grade thermo and rgb sensors to capture and analyze internal ear color and bulding, and body temperature, supported by proprietary AI algorithms trained to detect signs of infection. The system includes a mobile app that visualizes results, guides parents with next steps, and connects them to healthcare professionals when needed.

Otitest aims to reduce late diagnoses, unnecessary emergency visits, and antibiotic overuse, a major public health concern. It also empowers parents to make informed decisions, providing peace of mind and supporting timely care.

The solution combines hardware, software, and clinical intelligence, and is being developed under CE and FDA medical device regulations. A unique educational and gamified app experience complements the core diagnostics, building trust and engagement with families.

Otitest will launch as a B2C solution, sold directly to families, with optional B2B partnerships with pediatric clinics, pharmacies, and insurance providers.

CONTACT DETAILS

Raul Almeida

E-mail: raul.almeida@metabluesolution.com

Phone: +35 193 751 9368

Website: https://otitest.com

INNOMEDCATALYST

DEMO DAY InnoMedCatalyst 2025

TELEMATIC MEDICAL APPLICATIONS

Company Description

Telematic Medical Applications (TMA), headquartered in Piraeus, Greece, is a leading innovator in the field of eHealth and telemedicine solutions, leveraging over 26 years of expertise in healthcare technology integration. TMA's comprehensive approach combines advanced Health Information Systems (HIS), cutting-edge medical equipment, telemedicine platforms, and artificial intelligence (AI) to transform healthcare delivery, particularly in remote and underserved areas.

Key solutions include the ePokratis MedAiConnect app, offering secure cloud-based personal health records, contactless vital sign monitoring via AI, and teleconsultation services. Their No.A.H. (Ark of Health) Portable Telemedicine Kit, certified by INMARSAT, facilitates comprehensive medical assessments in isolated environments, like maritime and rural settings. The TMA MediStation and Epione AI Nurse Assistant further exemplify the company's commitment to seamless, efficient, and patient-centered digital healthcare.

TMA has successfully deployed nationwide telemedicine networks and eHealth solutions for Greece's National Health System, including digitalizing Syros General Hospital, connecting healthcare centers on remote islands, and enhancing the quality of care in maritime environments. Certified with multiple ISO standards, TMA ensures secure, high-quality, and regulatory-compliant implementations of healthcare technologies.

Organization name: Telematic Medical Applications Ltd

Country: Greece

Type of company: Innovative SME

Year of Foundation: 2007

TRL Level: TRL 6

Expected Revenue for the first 5Y after Market Launch: >1.000.000€

Funding Instrument: Grant

Investment Required: NA

Product / Solution

ePokratis MedAiConnect is an innovative B2C digital health platform designed to transform personal health management in Europe. Through an AI-powered mobile application, it enables users to monitor vital signs, store personal health records, and connect remotely with medical professionals for seamless, on-demand healthcare. Leveraging advanced AI and computer vision, it uses remote photoplethysmography (rPPG) to track blood flow variations via facial skin, allowing contactless measurement of heart rate, blood pressure, oxygen saturation, respiration rate, heart rate variability, stress index, and atrial fibrillation.

Users can also link compatible Bluetooth medical devices for comprehensive, real-time health monitoring. With its integrated telemedicine features, ePokratis MedAiConnect bridges the gap between patients and healthcare providers, offering accessible online consultations across Europe. By supporting preventive healthcare and providing proactive alerts on potential health issues, it empowers individuals to manage chronic conditions such as cardiovascular disease, diabetes, respiratory disorders, and mental health concerns more effectively.

Health records are securely stored in the cloud, ensuring data interoperability with EU health data exchanges, while giving users full control over who can access their data. Through these features, ePokratis MedAiConnect redefines the way individuals engage with their health, fostering a new era of personalized care.

CONTACT DETAILS

Marios Prasinos

E-mail: mprasinos@tma.gr

Phone: +30 211 116 5330

Website: https://tma.gr/

INNOMEDCATALYST

DEMO DAY InnoMedCatalyst 2025

MUSIQUENCE TECHNOLOGIES
be creative!

Company Description

Musiquence Technologies, Lda is an innovative startup based in Funchal, Madeira Island (postal code 9060-014 – Funchal). Our mission is to empower creators through no-code, AI-powered, and science-backed tools that enable the development of user-centric interactive solutions in both healthcare and education.

We are committed to transforming these sectors by delivering:

- Next-generation, science-driven solutions that bridge research and real-world application
- A patient- and learner-centered approach that prioritizes individual needs and inclusivity
- Enhanced quality of life, supported by accessible and effective digital tools

At the core of our work is a belief in the power of collaboration between content creators and their communities. By equipping professionals - such as educators, therapists, and caregivers, with intuitive and adaptable technology, we aim to spark lasting, positive change that benefits both individuals and society as a whole.

Our solutions are designed to reduce technical barriers, enabling anyone to personalize learning and therapeutic experiences. With a strong foundation in innovation and social impact, Musiquence Technologies is proud to be building the future of digital empowerment from Madeira to the world

Organization name: Musiquence Technologies

Country: Portugal

Type of company: Startup

Year of Foundation: 2022

TRL Level: TRL 6

Expected Revenue for the first 5Y after Market Launch: 0 - 50.000€

Funding Instrument: Grant

Investment Required: NA

Product / Solution

The solution is offered as a subscription-based and pay-per-use model, making it scalable and flexible for organizations of different sizes.

We are primarily targeting a B2B model, serving institutions, clinics, schools, and care centers, but with the potential to expand into B2C for individual professionals seeking personalized content creation tools.

CONTACT DETAILS

Luis Duarte Andrade Ferreira

E-mail: info@musiquencetechnologies.com

Phone: +35 196 932 9669

Website: https://musiquencetechnologies.com/

INNOMEDCATALYST

DEMO DAY InnoMedCatalyst 2025

Bloom

Company Description

Bloom is a B2B SaaS platform that connects dietitians and patients to support long-term diet management using personal bio-data and behavior patterns. It enables doctors to diagnose weight issues and create personalized nutrition plans based on medical check-ups and body metrics. The mobile app, as a module of patients, allows seamless communication, progress tracking, and support for challenges like travel, workload, or dining out, and any other issues that people following a diet may face.

Why Bloom?

- First B2B SaaS diet treatment solution for both doctors and patients, fixing main issues of therapy.
- Reduces paperwork, saving up to 30 minutes per visit.
- Helps diagnose accurately and develop highly personalized treatment plans, preventing health risks.
- Connects patients and doctors for seamless communication, progress tracking, and support.
- Tracks not just calories and macro/micro nutrients, but also patient behavior patterns.
- Uses only the latest nutrition therapy studies and recommendations.

Organization name: Bloom

Country: Portugal

Type of company: Startup

Year of Foundation: 2025

TRL Level: TRL 4

Expected Revenue for the first 5Y after Market Launch: >1.000.000€

Funding Instrument: Grant

Investment Required: 150.000€

Product / Solution

We're building an B2B AI platform for dietitians and their patients to improve KPIs of nutrition treatment, such as diet adherence, patient compliance, engagement metrics, health outcomes, and retention rate.

Bloom supports the process end-to-end, providing doctors with tools to:

- Diagnose accurately
- Develop personalized meal and treatment plans based on medical history and behavior patterns
- Track progress and follow-up
- Patients get a user-friendly and easy to use mobile application
- Doctor Interaction and AI assistant 24/7
- Track therapy progress
- Adjust diet based on current situation

We tested Bloom in 25 users, finding it saves up to 30 minutes per visit and improves diet efficiency by at least 25%.

CONTACT DETAILS

Oksana Kalashnikova

E-mail: oksana@bodybloom.ai

Phone: +35 191 034 0711

Website: https://www.bodybloom.ai

INNOMEDCATALYST

DEMO DAY InnoMedCatalyst 2025

AIgea Medical

Company Description

AIgea Medical is a MedTech startup.
We are a team of global experts and technical visionaries, which has founded AIgea Medical after a successful experience into a DeepTech startup. The AIgea Medical management team has more than 25 years of expertise in the MedTech and Radiology market, spanning a mix of IT experts and AI Scientists supported by a Clinical Advisory board accommodating radiologists and clinical experts.

Our mission is to screen less and diagnose better: we are focusing on Artificial Intelligence applied to radiology workflows and digital imaging. We support radiologists in early Breast Cancer screening by applying Image Recognition, Generative AI and Deep Neural Networks.

Organization name: AIGEA Medical

Country: Italy

Type of company: Startup

Year of Foundation: 2022

TRL Level: TRL 4

Expected Revenue for the first 5Y after Market Launch: >1.000.000€

Funding Instrument: Equity

Investment Required: 1.500.000€

Product / Solution

AIgea Medical offers DeepMammo, a solution based on proprietary AI technology for the augmentation of radiologists' performances in early breast cancer screening and detection, reducing costs of screenings.
DeepMammo supports Imaging workflows, improving diagnostic precision, reducing daily workloads and therefore improving clinical practice while reducing costs.
DeepMammo is available in two versions:
1. WORKLIST is focusing on specificity: it detects negative cases (up to 90%), which can be filtered and excluded from the radiologists reading.
2. TRIAGE is focusing on sensitivity: it sorts out positive cases, with suspicious cancer lesions. In this way urgent cases can be highlighted and quickly managed by radiologists.
DeepMammo TRIAGE can automatically sort out the 90% of negative cases, heavily reducing the workload, and the WORKLIST version can cross-check the 10% of suspicious cases, reducing errors and improper recalls.

Our business model is B2B and based on subscriptions. We sell DeepMammo as a SaaS service and charge a fee for every case to screen. Since DeepMammo uses a SaaS subscription business model, it's revenue model relies mostly on the accumulated growth of ARR from recurring income streams from existing customers. The main revenue stream is generated by pay-per-use of the two DeepMammo versions: Worklist and Triage.

CONTACT DETAILS
Carlo Aliprandi
E-mail: carlo@aigeamedical.com
Phone: +39 348 257 3282
Website: https://www.aigeamedical.com

INNOMEDCATALYST

DEMO DAY InnoMedCatalyst 2025

BIOLIBRARY
SUSTAINABLE HEALTH TECH SOLUTIONS

Company Description

Biolibrary is an online platform that allows orthopaedists and doctors to create in an automatic way custom ready-to-print 3d models of prostheses and muscule-skeletal devices. With its patented algorithm, it can shift the paradigm of the procedures to develop any prostheses or musculoskeletal devices.

The company aims to revolutionize the procedures for making any prosthesis or musculoskeletal support.

Organization name: Biolibrary

Country: Italy

Type of company: Innovative SME

Year of Foundation: 2016

TRL Level: TRL 4-5

Expected Revenue for the first 5Y after Market Launch: >1.000.000€

Funding Instrument: Equity

Investment Required: 500.000€

Product / Solution

The solution proposed in the Biolibrary project involves the use of a SaaS platform capable of providing operators with a library of 3D models for orthoses, available in the cloud, with automatic sizing of the orthosis device based on biometrics obtained with simple photographs of the affected body segment. The manufacturing process is automated and, although it may require a longer printing time than the packaging of a cast or a splint, this time does not involve any healthcare professional. The process is the subject of a patent filed at EU level (n. 007690243-0001) and Int. (PCT/EP2020/084228).

The project aims to develop the SaaS platform and certify it in MDR with CE marking, thus making the platform itself and the printed orthoses in output real medical devices (Class A Software as a Device and Class IIa non-invasive devices). At present, the proprietary technologies have a TLR of 3 for the SaaS platform and 5 for the prototypes of printed orthoses. The project phases include 1) the production of an MVP (cloud platform) on which to start the data collection for the production of scientific evidence useful for the implementation of the technical dossier; 2) the regulatory submission of the technical dossier to obtain marketing approval; 3) the start of marketing on markets with high technological receptivity in the MedTech sector (USA, China).

CONTACT DETAILS

Antonio Puce

E-mail: apuce@biolibrary.it

Phone: +39 347 335 3773

Website: https://www.biolibrary.it/en/

INNOMEDCATALYST

DEMO DAY InnoMedCatalyst 2025

Company Description

Ablute is focused on transforming healthcare diagnostics with innovative analysis solutions by integrating advanced health monitoring into daily routines. Our mission is to turn daily habits into powerful, non-invasive health tools. By combining AI-powered analytics, lab-on-chip technology, and multi-sensor integration, we enable early disease detection and continuous health tracking without disrupting the user's lifestyle.

Our platform is designed to be inclusive, autonomous, and scalable, offering real-time analysis of up to 16 urinary biomarkers alongside vital signs such as ECG, PPG, and bioimpedance. It works as a platform to integrate many other health monitoring technologies. Unlike existing solutions, ablute provides comprehensive health insights in one device, aiming to reduce reliance on hospital-based diagnostics and ease pressure on healthcare systems.

We serve both individual users and institutions through a flexible B2B and B2C subscription model, ensuring accessibility without the need for direct equipment ownership. Our approach is particularly impactful in underserved and remote areas, promoting health equity and prevention.

Our goal is to make health monitoring accessible to all and provide users with actionable health insights. ablute_ is committed to making advanced diagnostics accessible, improving health outcomes globally.

Organization name: Ablute

Country: Portugal

Type of company: Startup

Year of Foundation: 2019

TRL Level: TRL 4

Expected Revenue for the first 5Y after Market Launch: >1.000.000€

Funding Instrument: Equity

Investment Required: 1.000.000€

Product / Solution

We developed a smart toilet (ablute) designed to work as a platform to integrate autonomous health monitoring technologies (e.g., urinalysis, EKG, PPG). The system is 100% autonomous and provides immediate results. The goal is to transform everyday bathroom use into a complete health exam.

We began by developing the urinalysis system (LOC) by applying a scientifically proven technology. This technology allows the system to be reusable and doesn't require reagents or consumables. The LOC targets up to 16 relevant biomarkers simultaneously and the set of selected biomarkers can be adapted according to customer's needs. The toilet also integrates AI to analyze the data, taking into consideration the user's result history and personal data. This allows ablute to provide personalized health reports to each user and assess health risks.

Ablute is starting with a B2B model, first targeting pharmacies. These often offer in-house exams and are trusted by their customers, being the perfect environment to familiarize users with our solution. This technology can be adapted to other sectors such as wellness and fitness, thus these will be the second targeted sector, before expanding to a B2C model. One of the key advantages of ablute is that it offers the opportunity for everyone to commercially exploit its capabilities thanks to its subscription-based model. This, ads potential for business use and creates an extra incentive for individuals and organizations to purchase ablute.

CONTACT DETAILS

Alexandra Meira

E-mail: info@ablute.pt

Phone: +35 192 791 7886

Website: https://www.ablute.pt

INNOMEDCATALYST

DEMO DAY InnoMedCatalyst 2025

MEDRADAR

Company Description

We are the developers of the 1st totally free for patients, independent mobile app which allows patients to scan pharmacies inventory stock to identify the ones who have their prescribed medicines.

MedRadar brings pharmacies into the consumers pockets, showing opening hours, vaccination points and shops with own medicines preparation labs.
For pharmacies, MedRadar is the mobile digitalization partner, allowing them to have mobile presence and compete with large pharmacy chains. MedRadar is "uberizing" the e-pharmacy industry.

Organization name: MedRadar

Country: Romania

Type of company: Startup

Year of Foundation: 2024

TRL Level: TRL 6

Expected Revenue for the first 5Y after Market Launch: 250.000€ - 500.000€

Funding Instrument: Equity

Investment Required: 120.000€

Product / Solution

Medradar is a fully digital app which screens the inventory of the pharmacies near the patient allowing for rapid identification of the stores where the medication needed is available. Also, the app allows to find nearby pharmacies across the entire country i.e. pharmacies which can provide the flu vaccine on the spot or pharmacies with their own laboratory.

All these features bring the retail pharmaceutical market into the patient pocket.

CONTACT DETAILS
Cristian Radulescu
E-mail: cristian.radulescu@medradar.ro
Phone: +40 730 713 505
Website: https://www.medradar.ro

INNOMEDCATALYST

DEMO DAY InnoMedCatalyst 2025

geen
Health is your choice

Company Description

Geen is a FemTech startup pioneering precision healthcare through a proprietary AI-driven platform specifically focused on personalized sexual and reproductive health pathways. Founded by a multidisciplinary team combining deep expertise in gender data science, clinical AI algorithms, public health systems, and inclusive design, Geen deploys advanced Natural Language Processing (NLP) and Machine Learning (ML) triage technology.

Our digital assistant interprets user-reported symptoms, identifies specific health needs, and recommends the most appropriate clinical pathway. By integrating directly with healthcare providers' Electronic Health Records (EHRs) and scheduling systems, Geen significantly improves patient navigation, reducing diagnostic delays and system bottlenecks.

Geen's solution addresses the gender health data gap by systematically collecting structured, gender-disaggregated health data, crucial for predictive and preventive interventions. Currently at TRL 5, our system is undergoing patent application and has been piloted successfully within clinical environments. Geen offers its platform as a white-label solution to healthcare institutions (ASLs, hospitals) and corporates, optimizing public health resources and enhancing corporate welfare through improved employee health outcomes.

Organization name: Geen

Country: Italy

Type of company: Startup

Year of Foundation: 2024

TRL Level: TRL 5

Expected Revenue for the first 5Y after Market Launch: >1.000.000€

Funding Instrument: Equity

Investment Required: 600.000€ - 1.000.000€

Product / Solution

Geen is an AI-powered digital health platform designed to guide women and people with a uterus through personalized sexual and reproductive health journeys. Our core product is a virtual assistant that leverages Natural Language Processing (NLP) and a proprietary triage algorithm to interpret user-reported symptoms and recommend the most appropriate specialist or service. The system is trained with gender-specific clinical knowledge and structured to reduce diagnostic delays, inappropriate referrals, and unmet health needs—especially in areas like endometriosis, PCOS, menopause, and gender-affirming care.

Geen operates as both a B2C solution—providing free access to users via web and mobile—and a B2B/ B2G white-label platform for healthcare providers (ASLs, hospitals) and companies offering corporate health benefits. In institutional settings, it integrates with Electronic Health Records (EHRs) and appointment systems to optimize patient flow, reduce administrative load, and generate structured health data. This data improves clinical planning, early intervention, and equitable service delivery.

Currently at TRL 5 and in the process of patenting its triage model, Geen is a scalable, modular solution designed to work within regulated healthcare environments—bridging the gap between underserved populations and high-quality care.

CONTACT DETAILS
Giulia Marchese
E-mail: giulia@geenapp.it
Phone: +39 320 305 0545
Website: https://geenapp.it

INNOMEDCATALYST

DEMO DAY InnoMedCatalyst 2025

POINT PRESSURE

Company Description

Point Pressure is a clinical-stage Italo-Spanish company combining medical devices and digital health, dedicated to improving long-term mobility for patients with central nervous system injuries, including stroke, cerebral palsy, multiple sclerosis, traumatic brain injury (TBI), and spinal cord injury (SCI). The global neurorehabilitation market was valued at $2.73 billion in 2023, with an annual growth rate of 13% (CAGR).

Our solution consists of a treatment and a prognosis algorithm. First, the medical device evaluates patient biomarkers (muscle activation, muscle strength, and balance) to predict the patient's ability to regain autonomous gait using an AI (ML-based) algorithm. Based on this profile, the device delivers the required mechanical neuromodulation therapy to enhance movement recovery. The device (MDR Class I) applies precise mechanical stimulation, boosting the brain's capacity to integrate new movement patterns at both cortical and subcortical levels. In our latest clinical study, stroke patients who used the device for 8 weeks (three sessions per week) reduced their risk of falls by 75% (from 8 to 2 falls per year), while also improving balance, strength, and walking speed.

As a complement to the treatment, our companion app monitors patient progress, providing objective rehabilitation data for therapists and facilitating continuous monitoring and reporting on patient evolution.

Point Pressure expects to obtain MDR CE for its first device in 2025.

Organization name: Point Pressure

Country: Spain

Type of company: Startup

Year of Foundation: 2022

TRL Level: TRL 6

Expected Revenue for the first 5Y after Market Launch: 50.000€ - 100.000€

Funding Instrument: Equity

Investment Required: NA

Product / Solution

Point Pressure is developing Sura, a wearable medical device that delivers non-invasive neuromodulation to improve mobility and balance in patients with neurological disorders such as stroke, cerebral palsy, or multiple sclerosis. Through calibrated pressure on key sensory areas, the device stimulates the somatosensory system, promoting neuroplasticity and enabling the nervous system to relearn efficient movement patterns. Clinical data shows a 75% reduction in fall risk and notable gains in strength and walking speed after only 8 weeks of treatment.

Sura is paired with a digital platform that personalizes treatments and tracks patient progress, enhancing therapy adherence and clinical decision-making. The solution is designed for flexibility in care: it can be used in hospitals, rehabilitation centers, and home settings, making it scalable and cost-efficient.

The digital platform includes a prognosys algorythm capable of estimating (after-stroke) how much time will a patient require before readquiring functional gait.

The business model is primarily B2B, targeting hospitals, clinics, and rehabilitation providers, with potential B2B2C applications as professionals prescribe its use at home. It includes device sales, software subscriptions, and consumables, ensuring clinical value and recurring revenue.

CONTACT DETAILS

Marc Casellas

E-mail: marc@pointpressure.com

Phone: +34 618 011 058

Website: https://pointpressure.com

INNOMEDCATALYST

DEMO DAY InnoMedCatalyst 2025

Eldie

Company Description

Our company is dedicated to improving the lives of seniors through accessible and tailored technology.

With Europe's elderly population approaching 25%, we address this growing need by staying closely connected with seniors, identifying their real-world challenges, and developing tech-based solutions that are intuitive and empowering.

By bridging the gap between innovation and inclusivity, we aim to create a society where aging is met with dignity, independence, and digital support.

Organization name: Eldie

Country: Romania

Type of company: Startup

Year of Foundation: 2023

TRL Level: TRL 6

Expected Revenue for the first 5Y after Market Launch: >1.000.000€

Funding Instrument: Equity / Grants

Investment Required: 1.000.000€

Product / Solution

Eldie slows down mental deterioration among seniors using AI, scientifically proven mental games and quizzes. It helps middle-aged adults keep track of the evolution of seniors, by calculating their brain score.
Seniors interact with a proactive Virtual Friend that creates a personalized physical and mental activity plan and roll it out to integrate with their day-to-day habits.

Seniors have free access to the app, the ones that are paying are caretakers (family members, specialists, etc.).

The business model will be both B2B and B2C:
B2B - targeting care houses and corporations that want to offer Eldie accounts to their employees (as benefits)
B2C - directly to family members

CONTACT DETAILS
Ioan-Teofil Sturzoiu
E-mail: teofil.sturzoiu@gmail.com
Phone: +40 761 148 821
Website: https://eldie.ro/en

INNOMEDCATALYST

DEMO DAY
InnoMedCatalyst
2025

THERATECHNICA
INNOVATING HEALTHCARE

Company Description

Theratechnica is revolutionizing healthcare by integrating virtual reality, augmented reality, and AI into one seamless ecosystem that transforms how medical professionals train, treat, and diagnose.

From immersive VR surgical and nursing simulations to AI-powered diagnostics and AR-enhanced surgical tools, Theratechnica addresses the global medical error crisis and bridges the gap in digital healthcare training - delivering measurable results, scalability, and a future-proof solution for institutions and practitioners alike.

Organization name: Theratechnica

Country: Greece

Type of company: Startup

Year of Foundation: 2024

TRL Level: TRL 5

Expected Revenue for the first 5Y after Market Launch: >1.000.000€

Funding Instrument: Equity

Investment Required: 1.000.000€

Product / Solution

EarlyScan AI is Theratechnica's advanced B2B diagnostic solution designed to significantly improve early detection of pancreatic cancer—a condition with less than 11% five-year survival due to late diagnosis. Leveraging AI, it analyzes CT/MRI scans and clinical data to detect early-stage anomalies invisible to the human eye. The system offers radiologists an intuitive decision support dashboard with annotated imaging, confidence scores, and explainable outputs. It integrates seamlessly into hospital infrastructure (PACS/EHR) and is compliant with EU MDR standards.

EarlyScan AI is offered through a subscription-based and pay-per-scan licensing model to hospitals and diagnostic centers, enabling scalable and cost-efficient adoption. Currently in the pre-commercial phase, it is being validated in collaboration with the University General Hospital of Larissa and is on track for CE marking. With >96% accuracy in retrospective testing, EarlyScan AI promises to reduce diagnostic delays, improve surgical eligibility, and lower late-stage treatment costs—transforming how clinicians approach pancreatic cancer diagnostics.

CONTACT DETAILS
Georgios Kouvidis
E-mail: georgios.kouvidis@theratechnica.eu
Phone: +30 694 088 9486
Website: https://www.theratechnica.eu/en/

INNOMEDCATALYST

DEMO DAY InnoMedCatalyst 2025

VR·WORLD MEDTECH

Company Description

VR-World MedTech is a digital health startup based in the EU. We develop a VR platform for early neurorehabilitation of the central nervous system and balance disorders - after stroke, TBI, Parkinson's, and other conditions.

Unlike conventional tools that require the patient to stand, our system works from day one - even for bedridden or wheelchair-bound patients.

It combines real-time diagnostics, evidence-based protocols, and adaptive exercises. The system runs on standard commercial VR headsets.

Our team is fully based in the EU. We're currently raising a €600K pre-seed round to scale across Europe and finalize medical certification.

Organization name: VR-W MedTech

Country: Poland

Type of company: Startup

Year of Foundation: 2025

TRL Level: TRL 6

Expected Revenue for the first 5Y after Market Launch: >1.000.000€

Funding Instrument: NA

Investment Required: 600.000€

Product / Solution

VR-World MedTech is a VR-based platform for early neurorehabilitation after stroke, traumatic brain injury and other central nervous system (CNS) and balance disorders.
Unlike traditional solutions, it enables recovery from day one - even for bedridden or wheelchair-bound patients.
What's inside:

- Medically approved rehabilitation protocols
- Adaptive VR therapy
- Built-in diagnostics and progress tracking
- Doctor-controlled therapy management

Business model:

- B2B SaaS: €1200/year per 100 patients
- Pay-as-you-go for clinics with irregular patient flow
- VR hardware rental — through certified partners
- Future roadmap: B2C home therapy, AI-based personalization

Validation & Status:

- 1,000+ patients treated
- 6 clinical sites
- Protocol approved by the Ministry of Health (Belarus)
- Patent granted in Belarus; EU patent application submitted
- Winner at Wolf Summit 2025 (Warsaw) & awarded by Startup Terrace (Taiwan)
- Accepted into CUBiO Accelerator (USA)
- Team fully relocated to the EU
- Preparing for EU MDR certification

CONTACT DETAILS
Raman Tsimafeyeu
E-mail: ceo@vrworldmedtech.pl
Phone: +48 571 944 382
Website: http://vrworldmedtech.pl



Contact Us

Website: https://medicnest.eu/innomedcatalyst/

Email: innomedcatalyst@medicnest.eu

Funded by
the European Union